Accelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a note issued to investors on Sunday. The firm set a “hold” rating on the medical research company’s stock.

Separately, BTIG Research raised Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

Accelerate Diagnostics Price Performance

NASDAQ:AXDX opened at $1.13 on Friday. The company has a market capitalization of $28.30 million, a price-to-earnings ratio of -0.40 and a beta of 0.59. Accelerate Diagnostics has a 1-year low of $0.73 and a 1-year high of $3.05. The business has a 50 day moving average of $1.47 and a 200 day moving average of $1.54.

Insider Activity

In related news, Director John Patience acquired 200,000 shares of the stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average cost of $1.57 per share, for a total transaction of $314,000.00. Following the completion of the acquisition, the director now directly owns 653,224 shares of the company’s stock, valued at approximately $1,025,561.68. This represents a 44.13 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 43.60% of the company’s stock.

Institutional Investors Weigh In On Accelerate Diagnostics

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd bought a new stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned approximately 0.08% of Accelerate Diagnostics at the end of the most recent quarter. Hedge funds and other institutional investors own 17.14% of the company’s stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.